Zeta TROP2 Antibody. Zeta’s recombinant rabbit antibody recognizes TROP2 (Trophoblast cell surface antigen 2), which is expressed in many epithelial neoplasms. TROP2 deregulation can be associated with cancer progression in a tumor-type dependent manner.
TROP2 (also known ast EpCAM2) is a cell surface glycoprotein receptor with a single-pass type I membrane containing one thyroglobulin type-1 domain, an epidermal growth factor-like repeat, a phosphatidylinositol binding site, and tyrosine phosphorylation sites near the C-terminus. TROP2 plays a role in transducing intracellular calcium signals, and TROP2 acts as a cell surface receptor with a role in cell self-renewal, proliferation, and transformation. TROP2 is expressed in trophoblast cells, cornea, and multi-stratified epithelia. In embryonic development, TROP2 plays a critical role in placenta formation, embryo implantation, stem cell proliferation, and organ development. Additionally, TROP2 is highly expressed in several types of tumors and is involved in regulating the growth of carcinoma cells.
Finally, TROP2 is the target of sacituzumab govitecan, an antibody-drug conjugate approved for treatment of triple negative breast cancer and urothelial carcinoma. The drug has demonstrated significant clinical benefit in metastatic triple negative breast cancer, hormone-positive breast cancer, small-cell lung cancer, nonsmall-cell lung cancer, and metastatic urothelial carcinomas.